A study on genetic linkages between aberrant lipid metabolism and PD directly demonstrates that glucocerebrosidase and sphingomyelin phosphodiesterase 1 mutations enhance PD risk in humans, and that galactosylceramide beta hydrolase function loss increases α-synuclein aggregation and accumulation in experimental murine models. The gene discussed is SMPD1; the disease is Parkinson disease.